您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Quinacrine(hydrochloride hydrate)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Quinacrine(hydrochloride hydrate)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Quinacrine(hydrochloride hydrate)图片
规格:98%
分子量:472.9
包装与价格:
包装价格(元)
100mg电议
500mg电议
1g电议
5g电议

产品介绍
voltage-dependent sodium channels blocker
货号:ajcx11140
CAS:N/A
分子式:C23H30ClN3O ? 2HCl [XH2O]
分子量:472.9
溶解度:≥ 18.65mg/mL in H2O
纯度:98%
存储:Store at -20°C
库存:现货

Background:

IC50: 3.3 μM

Ki = 6.7 μM

Quinacrine, also commonly known as atebrine, is a compound which is commonly used as an anti-protozoal agent. It inhibits voltage-dependent sodium channels with an IC50 value of 3.3 μM and suppresses aldehyde oxidase with an IC50 value of 3.3 μM. Quinacrine prevents misfolding of prion protein with an EC50 value of 0.3 μM. As an effective riboflavin antagonist, quinacrine associates with the riboflavin-binding protein with a Ki value of 6.7 μM. Voltage-dependent sodium channels play a vital role in action potential initiation and propagation in excitable cells, including muscle, nerve, and neuroendocrine cell types.

In vitro: Quinacrine, in a dose-dependent manner, effectively reversed the resistance in the multi-drug resistance (MDR) K562 cells. Quinacrine displayed strong toxicity to the MDR K562 cells at a concentration of 10.0 μM. Compared to the control, quinacrine significantly increased the activity of caspase-9 and -3 activities in the MDR K562 and K562 cells in a dose-dependent fashion [1].

In vivo: Female BALB/c nude mice, bearing MDR K562 cell xenografts, were injected with quinacrine at a dose of 10 mg/kg via tail vein for 13 days. Compared to the control group, quinacrine inhibited the tumor growth obviously in the treated groups. Furthermore, quinacrine enhanced the anti-tumor effects of vincristine [1].

参考文献:
[1].Liang, G.?, Lu, W., Wu, J., Zhao, J., Hong, H., & Long, C. et al. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundamental & Clinical Pharmacology.2008; 22(4): 429-437.